Key result
Atrial fibrillation screening remains debated, with experts disagreeing on whether current evidence justifies implementation or if randomized trials are needed to avoid overdiagnosis.
Why the study?
Should we screen for atrial fibrillation?
Should we screen for atrial fibrillation?
This editorial debates the readiness for a national atrial fibrillation screening program, contrasting the sufficiency of current evidence against the risk of overdiagnosis and the need for randomized trials.
Current evidence is sufficient to justify a national screening programme, argues Mark Lown, but Patrick Moran thinks there are too many unanswered questions and evidence from randomised trials is needed to avoid overdiagnosis
No takes yet. Share an insight, caveat, or question.
Lown et al. (2019) studied this question. Atrial fibrillation screening remains debated, with experts disagreeing on whether current evidence justifies implementation or if randomized trials are needed to avoid overdiagnosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: